Key result
Genetic polymorphisms in MME, BDKRB2, PTGER3, and ACE genes are associated with susceptibility to ACE inhibitor-induced cough.
Why the study?
Are specific genetic polymorphisms associated with susceptibility to ACEi-induced cough in hypertensive patients?
Observational
Are specific genetic polymorphisms associated with susceptibility to ACEi-induced cough in hypertensive patients?
Specific genetic polymorphisms in MME, BDKRB2, PTGER3, and ACE genes, as well as epistatic interactions, significantly modify the risk of developing ACEi-induced cough.
Answers are grounded in this paper and cite their sources.
May support risk stratification for ACEi cough; leaves open prospective validation before clinical genetic testing.
BACKGROUND AND OBJECTIVE: Angiotensin-converting enzyme inhibitors (ACEi) are the first selected drugs for hypertensive patients because of its protective properties against heart and kidney diseases. Persistent cough is a common adverse reaction associated with ACEi, which can bind to the treatment cessation, but its etiology remains an unresolved issue. The most accepted mechanism is that the inhibition of ACEi increases kinins levels, resulting in the activation of proinflammatory mechanisms and nitric oxide generation. However, relatively little is known about the genetic susceptibility to ACEi-induced cough in hypertensive patients. METHODS: We carried out a monogenic association analysis of 39 polymorphisms and haplotypes in genes encoding key proteins related to ACEi activity with the occurrence of ACEi-induced cough. We also carried out a digenic association analysis and investigated the existence of epistatic interactions between the analyzed polymorphisms using a logistic regression procedure. Finally, we investigated the predictive value of the identified associations for ACEi-induced cough. RESULTS: We found that genetic polymorphisms in MME [rs2016848, P=0.002, odds ratio (OR)=1.795], BDKRB2 (rs8012552, P=0.012, OR=1.609), PTGER3 (rs11209716, P=0.002, OR=0.565), and ACE (rs4344) genes are associated with ACEi-related cough. For the latter, the effect is sex specific, having a protective effect in males (P=0.027, OR=0.560) and increasing the risk in females (P=0.031, OR=1.847). In addition, genetic interactions between peptidases involved in kinins levels (CPN1 and XPNPEP1) and proteins related to prostaglandin metabolism (PTGIS and PTGIR) strongly modify the risk of ACEi-induced cough presentation (0.102≤OR≤0.384 for protective combinations and 2.732≤OR≤7.216 for risk combinations). CONCLUSION: These results are consistent with the hypothesis that the mechanism of cough is related to the accumulation of bradykinin, substance P, and prostaglandins.
No takes yet. Share an insight, caveat, or question.
Grilo et al. (2010) conducted an observational in ACE inhibitor-induced cough in hypertension. Genetic polymorphisms (MME, BDKRB2, PTGER3, ACE) was evaluated on ACEi-induced cough (OR 1.795, p=0.002). Genetic polymorphisms in MME, BDKRB2, PTGER3, and ACE genes are associated with susceptibility to ACE inhibitor-induced cough.
Synapse has enriched 10 related papers. Consider them for comparative context: